SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-19-067216
Filing Date
2019-03-07
Accepted
2019-03-07 16:15:02
Documents
7
Period of Report
2019-03-06
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d714508d8k.htm 8-K 22637
2 EX-1.1 d714508dex11.htm EX-1.1 166581
3 EX-5.1 d714508dex51.htm EX-5.1 10161
4 EX-99.1 d714508dex991.htm EX-99.1 8189
5 GRAPHIC g714508dsp46.jpg GRAPHIC 10938
6 GRAPHIC g714508g0307211833650.jpg GRAPHIC 1649
7 GRAPHIC g714508g0307212322163.jpg GRAPHIC 3627
  Complete submission text file 0001193125-19-067216.txt   231524
Mailing Address 6400 WESTWIND WAY SUITE A CRESTWOOD KY 40014
Business Address 6400 WESTWIND WAY SUITE A CRESTWOOD KY 40014 502-241-4114
Apellis Pharmaceuticals, Inc. (Filer) CIK: 0001492422 (see all company filings)

IRS No.: 271537290 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38276 | Film No.: 19666018
SIC: 2834 Pharmaceutical Preparations